1
|
Bolton SJ, Levin SM, Guillot T, Li C, Kaspi Y, Orton G, Wong MH, Oyafuso F, Allison M, Arballo J, Atreya S, Becker HN, Bloxham J, Brown ST, Fletcher LN, Galanti E, Gulkis S, Janssen M, Ingersoll A, Lunine JL, Misra S, Steffes P, Stevenson D, Waite JH, Yadav RK, Zhang Z. Microwave observations reveal the deep extent and structure of Jupiter's atmospheric vortices. Science 2021; 374:968-972. [PMID: 34709937 DOI: 10.1126/science.abf1015] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
[Figure: see text].
Collapse
Affiliation(s)
- S J Bolton
- Southwest Research Institute, San Antonio, TX, USA
| | - S M Levin
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA, USA
| | - T Guillot
- Université Côte d'Azur, Observatoire de la Côte d'Azur, Centre National de la Recherche Scientifique, Laboratoire Lagrange, Nice, France
| | - C Li
- Department of Climate and Space Sciences and Engineering, University of Michigan, Ann Arbor, MI, USA
| | - Y Kaspi
- Weizmann Institute of Science, Rehovot, 76100, Israel
| | - G Orton
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA, USA
| | - M H Wong
- Carl Sagan Center for Research, SETI Institute, Mountain View, CA, USA
| | - F Oyafuso
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA, USA
| | - M Allison
- Goddard Institute for Space Studies, New York, NY, USA.,Department of Astronomy, Columbia University, New York, NY 10027, USA
| | - J Arballo
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA, USA
| | - S Atreya
- Department of Climate and Space Sciences and Engineering, University of Michigan, Ann Arbor, MI, USA
| | - H N Becker
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA, USA
| | - J Bloxham
- Department of Earth and Planetary Sciences, Harvard University, Cambridge, MA 02138, USA
| | - S T Brown
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA, USA
| | - L N Fletcher
- School of Physics and Astronomy, University of Leicester, Leicester LE1 7RH, UK
| | - E Galanti
- Weizmann Institute of Science, Rehovot, 76100, Israel
| | - S Gulkis
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA, USA
| | - M Janssen
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA, USA
| | - A Ingersoll
- Department of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA, USA
| | - J L Lunine
- Department of Astronomy, Cornell University, Ithaca, NY, USA
| | - S Misra
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA, USA
| | - P Steffes
- Department of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, USA
| | - D Stevenson
- Department of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA, USA
| | - J H Waite
- Southwest Research Institute, San Antonio, TX, USA
| | - R K Yadav
- Department of Earth and Planetary Sciences, Harvard University, Cambridge, MA 02138, USA
| | - Z Zhang
- Department of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA, USA
| |
Collapse
|
2
|
Hueso R, Guillot T, Sánchez-Lavega A. Convective storms and atmospheric vertical structure in Uranus and Neptune. Philos Trans A Math Phys Eng Sci 2020; 378:20190476. [PMID: 33161859 PMCID: PMC7658788 DOI: 10.1098/rsta.2019.0476] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 08/27/2020] [Indexed: 05/20/2023]
Abstract
The ice giants Uranus and Neptune have hydrogen-based atmospheres with several constituents that condense in their cold upper atmospheres. A small number of bright cloud systems observed in both planets are good candidates for moist convective storms, but their observed properties (size, temporal scales and cycles of activity) differ from moist convective storms in the gas giants. These clouds and storms are possibly due to methane condensation and observations also suggest deeper clouds of hydrogen sulfide (H2S) at depths of a few bars. Even deeper, thermochemical models predict clouds of ammonia hydrosulfide (NH4SH) and water at pressures of tens to hundreds of bars, forming extended deep weather layers. Because of hydrogen's low molecular weight and the high abundance of volatiles, their condensation imposes a strongly stabilizing vertical gradient of molecular weight larger than the equivalent one in Jupiter and Saturn. The resulting inhibition of vertical motions should lead to a moist convective regime that differs significantly from the one occurring on nitrogen-based atmospheres like those of Earth or Titan. As a consequence, the thermal structure of the deep atmospheres of Uranus and Neptune is not well understood. Similar processes might occur at the deep water cloud of Jupiter in Saturn, but the ice giants offer the possibility to study these physical aspects in the upper methane cloud layer. A combination of orbital and in situ data will be required to understand convection and its role in atmospheric dynamics in the ice giants, and by extension, in hydrogen atmospheres including Jupiter, Saturn and giant exoplanets. This article is part of a discussion meeting issue 'Future exploration of ice giant systems'.
Collapse
Affiliation(s)
- R. Hueso
- Física Aplicada I, Escuela de Ingeniería de Bilbao, UPV/EHU, 48013 Bilbao, Spain
| | - T. Guillot
- Université Côte d’Azur, Laboratoire Lagrange, OCA, CNRS UMR 7293, Nice, France
| | - A. Sánchez-Lavega
- Física Aplicada I, Escuela de Ingeniería de Bilbao, UPV/EHU, 48013 Bilbao, Spain
| |
Collapse
|
3
|
Kaspi Y, Galanti E, Hubbard WB, Stevenson DJ, Bolton SJ, Iess L, Guillot T, Bloxham J, Connerney JEP, Cao H, Durante D, Folkner WM, Helled R, Ingersoll AP, Levin SM, Lunine JI, Miguel Y, Militzer B, Parisi M, Wahl SM. Jupiter's atmospheric jet streams extend thousands of kilometres deep. Nature 2018. [PMID: 29516995 DOI: 10.1038/nature25793] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The depth to which Jupiter's observed east-west jet streams extend has been a long-standing question. Resolving this puzzle has been a primary goal for the Juno spacecraft, which has been in orbit around the gas giant since July 2016. Juno's gravitational measurements have revealed that Jupiter's gravitational field is north-south asymmetric, which is a signature of the planet's atmospheric and interior flows. Here we report that the measured odd gravitational harmonics J3, J5, J7 and J9 indicate that the observed jet streams, as they appear at the cloud level, extend down to depths of thousands of kilometres beneath the cloud level, probably to the region of magnetic dissipation at a depth of about 3,000 kilometres. By inverting the measured gravity values into a wind field, we calculate the most likely vertical profile of the deep atmospheric and interior flow, and the latitudinal dependence of its depth. Furthermore, the even gravity harmonics J8 and J10 resulting from this flow profile also match the measurements, when taking into account the contribution of the interior structure. These results indicate that the mass of the dynamical atmosphere is about one per cent of Jupiter's total mass.
Collapse
Affiliation(s)
- Y Kaspi
- Department of Earth and Planetary Sciences, Weizmann Institute of Science, Rehovot 76100, Israel
| | - E Galanti
- Department of Earth and Planetary Sciences, Weizmann Institute of Science, Rehovot 76100, Israel
| | - W B Hubbard
- Lunar and Planetary Laboratory, University of Arizona, Tucson, Arizona 85721, USA
| | - D J Stevenson
- Divison of Geological and Planetary Sciences, California Institute of Technology, Pasadena, California 91125, USA
| | - S J Bolton
- Southwest Research Institute, San Antonio, Texas 78238, USA
| | - L Iess
- Department of Mechanical and Aerospace Engineering, Sapienza Universita di Roma, 00184 Rome, Italy
| | - T Guillot
- Université Côte d'Azur, OCA, Lagrange CNRS, 06304 Nice, France
| | - J Bloxham
- Department of Earth and Planetary Sciences, Harvard University, Cambridge, Massachusetts 02138, USA
| | - J E P Connerney
- Space Research Corporation, Annapolis, Maryland 21403, USA.,NASA/GSFC, Greenbelt, Maryland 20771, USA
| | - H Cao
- Divison of Geological and Planetary Sciences, California Institute of Technology, Pasadena, California 91125, USA.,Department of Earth and Planetary Sciences, Harvard University, Cambridge, Massachusetts 02138, USA
| | - D Durante
- Department of Mechanical and Aerospace Engineering, Sapienza Universita di Roma, 00184 Rome, Italy
| | - W M Folkner
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, California 91109, USA
| | - R Helled
- Institute for Computational Science, Center for Theoretical Astrophysics and Cosmology, University of Zurich, 8057 Zurich, Switzerland
| | - A P Ingersoll
- Divison of Geological and Planetary Sciences, California Institute of Technology, Pasadena, California 91125, USA
| | - S M Levin
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, California 91109, USA
| | - J I Lunine
- Department of Astronomy, Cornell University, Ithaca, New York 14853, USA
| | - Y Miguel
- Université Côte d'Azur, OCA, Lagrange CNRS, 06304 Nice, France.,Leiden Observatory, University of Leiden, Leiden, The Netherlands
| | - B Militzer
- Department of Earth and Planetray Science, University of California, Berkeley, California 94720, USA
| | - M Parisi
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, California 91109, USA
| | - S M Wahl
- Department of Earth and Planetray Science, University of California, Berkeley, California 94720, USA
| |
Collapse
|
4
|
Guillot T, Roche S, Rippert P, Hamroun D, Iwaz J, Ecochard R, Vuillerot C. Is Going Beyond Rasch Analysis Necessary to Assess the Construct Validity of a Motor Function Scale? Arch Phys Med Rehabil 2018; 99:1776-1782.e9. [PMID: 29625093 DOI: 10.1016/j.apmr.2018.02.017] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2017] [Revised: 02/09/2018] [Accepted: 02/23/2018] [Indexed: 10/17/2022]
Abstract
OBJECTIVE To examine whether a Rasch analysis is sufficient to establish the construct validity of the Motor Function Measure (MFM) and discuss whether weighting the MFM item scores would improve the MFM construct validity. DESIGN Observational cross-sectional multicenter study. SETTING Twenty-three physical medicine departments, neurology departments, or reference centers for neuromuscular diseases. PARTICIPANTS Patients (N=911) aged 6 to 60 years with Charcot-Marie-Tooth disease (CMT), facioscapulohumeral dystrophy (FSHD), or myotonic dystrophy type 1 (DM1). INTERVENTIONS None. MAIN OUTCOME MEASURE(S) Comparison of the goodness-of-fit of the confirmatory factor analysis (CFA) model vs that of a modified multidimensional Rasch model on MFM item scores in each considered disease. RESULTS The CFA model showed good fit to the data and significantly better goodness of fit than the modified multidimensional Rasch model regardless of the disease (P<.001). Statistically significant differences in item standardized factor loadings were found between DM1, CMT, and FSHD in only 6 of 32 items (items 6, 27, 2, 7, 9 and 17). CONCLUSIONS For multidimensional scales designed to measure patient abilities in various diseases, a Rasch analysis might not be the most convenient, whereas a CFA is able to establish the scale construct validity and provide weights to adapt the item scores to a specific disease.
Collapse
Affiliation(s)
- Tiffanie Guillot
- Service de Biostatistique-Bioinformatique, Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France
| | - Sylvain Roche
- Service de Biostatistique-Bioinformatique, Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France; Université de Lyon, Lyon, France; Université Lyon 1, Villeurbanne, France; CNRS UMR 5558, Laboratoire de Biométrie et Biologie Évolutive, Équipe Biostatistique Santé, Pierre-Bénite, France
| | - Pascal Rippert
- Hospices Civils de Lyon, Pôle Information Médicale, Évaluation, Recherche, Lyon, France
| | - Dalil Hamroun
- Direction de la Recherche et de l'Innovation, Centre Hospitalo-Universitaire de Montpellier, Montpellier, France
| | - Jean Iwaz
- Service de Biostatistique-Bioinformatique, Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France; Université de Lyon, Lyon, France; Université Lyon 1, Villeurbanne, France; CNRS UMR 5558, Laboratoire de Biométrie et Biologie Évolutive, Équipe Biostatistique Santé, Pierre-Bénite, France
| | - René Ecochard
- Service de Biostatistique-Bioinformatique, Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France; Université de Lyon, Lyon, France; Université Lyon 1, Villeurbanne, France; CNRS UMR 5558, Laboratoire de Biométrie et Biologie Évolutive, Équipe Biostatistique Santé, Pierre-Bénite, France
| | - Carole Vuillerot
- Université de Lyon, Lyon, France; Université Lyon 1, Villeurbanne, France; CNRS UMR 5558, Laboratoire de Biométrie et Biologie Évolutive, Équipe Biostatistique Santé, Pierre-Bénite, France; L'Escale, Service de Médecine Physique et de Réadaptation Pédiatrique, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France.
| | | |
Collapse
|
5
|
Guillot T, Miguel Y, Militzer B, Hubbard WB, Kaspi Y, Galanti E, Cao H, Helled R, Wahl SM, Iess L, Folkner WM, Stevenson DJ, Lunine JI, Reese DR, Biekman A, Parisi M, Durante D, Connerney JEP, Levin SM, Bolton SJ. A suppression of differential rotation in Jupiter’s deep interior. Nature 2018. [DOI: 10.1038/nature25775] [Citation(s) in RCA: 132] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
6
|
Bolton SJ, Adriani A, Adumitroaie V, Allison M, Anderson J, Atreya S, Bloxham J, Brown S, Connerney JEP, DeJong E, Folkner W, Gautier D, Grassi D, Gulkis S, Guillot T, Hansen C, Hubbard WB, Iess L, Ingersoll A, Janssen M, Jorgensen J, Kaspi Y, Levin SM, Li C, Lunine J, Miguel Y, Mura A, Orton G, Owen T, Ravine M, Smith E, Steffes P, Stone E, Stevenson D, Thorne R, Waite J, Durante D, Ebert RW, Greathouse TK, Hue V, Parisi M, Szalay JR, Wilson R. Jupiter's interior and deep atmosphere: The initial pole-to-pole passes with the Juno spacecraft. Science 2018; 356:821-825. [PMID: 28546206 DOI: 10.1126/science.aal2108] [Citation(s) in RCA: 186] [Impact Index Per Article: 31.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2016] [Accepted: 05/01/2017] [Indexed: 11/02/2022]
Abstract
On 27 August 2016, the Juno spacecraft acquired science observations of Jupiter, passing less than 5000 kilometers above the equatorial cloud tops. Images of Jupiter's poles show a chaotic scene, unlike Saturn's poles. Microwave sounding reveals weather features at pressures deeper than 100 bars, dominated by an ammonia-rich, narrow low-latitude plume resembling a deeper, wider version of Earth's Hadley cell. Near-infrared mapping reveals the relative humidity within prominent downwelling regions. Juno's measured gravity field differs substantially from the last available estimate and is one order of magnitude more precise. This has implications for the distribution of heavy elements in the interior, including the existence and mass of Jupiter's core. The observed magnetic field exhibits smaller spatial variations than expected, indicative of a rich harmonic content.
Collapse
Affiliation(s)
- S J Bolton
- Southwest Research Institute, San Antonio, TX 78238, USA.
| | - A Adriani
- Institute for Space Astrophysics and Planetology, National Institute for Astrophysics, 00133 Rome, Italy
| | - V Adumitroaie
- Jet Propulsion Laboratory/Caltech, Pasadena, CA 91109, USA
| | - M Allison
- Goddard Institute for Space Studies, New York, NY 10025, USA
| | - J Anderson
- Southwest Research Institute, San Antonio, TX 78238, USA
| | - S Atreya
- University of Michigan, Ann Arbor, MI 48109, USA
| | - J Bloxham
- Harvard University, Cambridge, MA 02138, USA
| | - S Brown
- Jet Propulsion Laboratory/Caltech, Pasadena, CA 91109, USA
| | - J E P Connerney
- Space Research Corporation, Annapolis, MD 21403, USA.,NASA Goddard Space Flight Center, Greenbelt, MD 20771, USA
| | - E DeJong
- Jet Propulsion Laboratory/Caltech, Pasadena, CA 91109, USA
| | - W Folkner
- Jet Propulsion Laboratory/Caltech, Pasadena, CA 91109, USA
| | - D Gautier
- Laboratoire d'Études Spatiales et d'Instrumentation en Astrophysique, Observatoire de Paris, 92195 Meudon, France
| | - D Grassi
- Institute for Space Astrophysics and Planetology, National Institute for Astrophysics, 00133 Rome, Italy
| | - S Gulkis
- Jet Propulsion Laboratory/Caltech, Pasadena, CA 91109, USA
| | - T Guillot
- Université Côte d'Azur, Observatoire de la Côte d'Azur, Laboratoire Lagrange CNRS, 06304 Nice, France
| | - C Hansen
- Planetary Science Institute, Tucson, AZ 85719, USA
| | - W B Hubbard
- Lunar and Planetary Laboratory, University of Arizona, Tucson, AZ 85721, USA
| | - L Iess
- Sapienza University of Rome, 00185 Rome, Italy
| | - A Ingersoll
- California Institute of Technology, Pasadena, CA 91125, USA
| | - M Janssen
- Jet Propulsion Laboratory/Caltech, Pasadena, CA 91109, USA
| | - J Jorgensen
- National Space Institute, Technical University of Denmark, 2800 Kongens Lyngby, Denmark
| | - Y Kaspi
- Department of Earth and Planetary Sciences, Weizmann Institute of Science, Rehovot 76100, Israel
| | - S M Levin
- Jet Propulsion Laboratory/Caltech, Pasadena, CA 91109, USA
| | - C Li
- California Institute of Technology, Pasadena, CA 91125, USA
| | - J Lunine
- Cornell University, Ithaca, NY 14853, USA
| | - Y Miguel
- Université Côte d'Azur, Observatoire de la Côte d'Azur, Laboratoire Lagrange CNRS, 06304 Nice, France
| | - A Mura
- Institute for Space Astrophysics and Planetology, National Institute for Astrophysics, 00133 Rome, Italy
| | - G Orton
- Jet Propulsion Laboratory/Caltech, Pasadena, CA 91109, USA
| | - T Owen
- Institute for Astronomy, University of Hawaii at Manoa, Honolulu, HI 96822, USA
| | - M Ravine
- Malin Space Science Systems, San Diego, CA 92121, USA
| | - E Smith
- Jet Propulsion Laboratory/Caltech, Pasadena, CA 91109, USA
| | - P Steffes
- Center for Space Technology and Research, Georgia Institute of Technology, Atlanta, GA 30332, USA
| | - E Stone
- California Institute of Technology, Pasadena, CA 91125, USA
| | - D Stevenson
- California Institute of Technology, Pasadena, CA 91125, USA
| | - R Thorne
- Department of Atmospheric and Oceanic Sciences, University of California, Los Angeles, CA 90095, USA
| | - J Waite
- Southwest Research Institute, San Antonio, TX 78238, USA
| | - D Durante
- Sapienza University of Rome, 00185 Rome, Italy
| | - R W Ebert
- Southwest Research Institute, San Antonio, TX 78238, USA
| | - T K Greathouse
- Southwest Research Institute, San Antonio, TX 78238, USA
| | - V Hue
- Southwest Research Institute, San Antonio, TX 78238, USA
| | - M Parisi
- Jet Propulsion Laboratory/Caltech, Pasadena, CA 91109, USA
| | - J R Szalay
- Southwest Research Institute, San Antonio, TX 78238, USA
| | - R Wilson
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO 80303, USA
| |
Collapse
|
7
|
Abstract
Mesotherapy, which is the injection of substances locally into mesodermally derived subcutaneous tissue, developed from empirical observations of a French physician in the 1950s. Although popular in Europe for many medical purposes, it is used for local cosmetic fat reduction in the United States. This paper reviews manuscripts indexed in PubMed/MEDLINE under 'mesotherapy', which pertains to local fat reduction. The history of lipolytic mesotherapy, the physiology of body fat distribution, the mechanism of action of different lipolytic stimulators and their increased efficacy in combination are reviewed. Mesotherapy falls into two categories. Lipolytic mesotherapy using lipolytic stimulators requires more frequent treatments as the fat cells are not destroyed and can refill over time. Ablative mesotherapy destroys fat cells with a detergent, causes inflammation and scarring from the fat necrosis, but requires fewer treatments. The historic and empiric mixing of sodium channel blocking local anaesthetics in mesotherapy solutions inhibits the intended lipolysis. Major mesotherapy safety concerns include injection site infections from poor sterile technique. Cosmetic mesotherapy directs the area from which fat is lost to improve self-image. Studies were of relatively small number, many with limited sample sizes. Future research should be directed towards achieving a Food and Drug Administration indication rather than continuing expansion of off-label use.
Collapse
Affiliation(s)
- S Jayasinghe
- Rollins School of Public Health, Atlanta, GA, USA
| | | | | | | |
Collapse
|
8
|
Crouzet N, Guillot T, Agabi K, Daban JB, Abe L, Mekarnia D, Rivet JP, Fanteï-Caujolle Y, Fressin F, Gouvret C, Schmider FX, Valbousquet F, Blazit A, Rauer H, Erikson A, Fruth T, Aigrain S, Pont F, Barbieri M. ASTEP: Towards the detection and characterization of exoplanets from Dome C. EPJ Web of Conferences 2011. [DOI: 10.1051/epjconf/20101106001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
|
10
|
Burrows A, Guillot T, Hubbard WB, Marley MS, Saumon D, Lunine JI, Sudarsky D. On the Radii of Close-in Giant Planets. Astrophys J 2000; 534:L97-L100. [PMID: 10790080 DOI: 10.1086/312638] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/18/2000] [Accepted: 03/09/2000] [Indexed: 05/23/2023]
Abstract
The recent discovery that the close-in extrasolar giant planet HD 209458b transits its star has provided a first-of-its-kind measurement of the planet's radius and mass. In addition, there is a provocative detection of the light reflected off of the giant planet tau Bootis b. Including the effects of stellar irradiation, we estimate the general behavior of radius/age trajectories for such planets and interpret the large measured radii of HD 209458b and tau Boo b in that context. We find that HD 209458b must be a hydrogen-rich gas giant. Furthermore, the large radius of a close-in gas giant is not due to the thermal expansion of its atmosphere but to the high residual entropy that remains throughout its bulk by dint of its early proximity to a luminous primary. The large stellar flux does not inflate the planet but retards its otherwise inexorable contraction from a more extended configuration at birth. This implies either that such a planet was formed near its current orbital distance or that it migrated in from larger distances (>/=0.5 AU), no later than a few times 107 yr of birth.
Collapse
|
11
|
Haicheur N, Escudier B, Dorval T, Negrier S, De Mulder PH, Dupuy JM, Novick D, Guillot T, Wolf S, Pouillart P, Fridman WH, Tartour E. Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients. Clin Exp Immunol 2000; 119:28-37. [PMID: 10606961 PMCID: PMC1905550 DOI: 10.1046/j.1365-2249.2000.01112.x] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/29/1999] [Indexed: 12/12/2022] Open
Abstract
This study shows that subcutaneous administration of increasing doses of IL-12, once a week, in 21 cancer patients increased the expression of cytokine genes (interferon-gamma (IFN-gamma), tumour necrosis factor-alpha (TNF-alpha), IP-10, MIG, IL-10, IL-4) in peripheral blood mononuclear cells even at very low doses (30 ng/kg). Surprisingly, no circulating TNF-alpha or IL-4 could be detected in the plasma of patients treated with IL-12. However, a marked increase of soluble IL-4 receptor was demonstrated in the plasma of five of the six patients studied, which may represent an additional mechanism by which IL-12 inhibits the development of the Th2 response in vivo. A marked decline of IFN-gamma and IP10 induction was recorded after repeated cycles of IL-12. In contrast, in most patients IL-12 increased IL-10 expression with no subsequent decrease during the course of therapy, and even an earlier peak of IL-10 induction at the 6th cycle. In addition, a constant up-regulation of serum soluble IFN-gamma receptor levels was observed after each cycle of IL-12 treatment with a delayed peak compared with the IFN-gamma peak. The constant rise of IL-10 and soluble IFN-gamma receptor during IL-12 therapy may therefore contribute to the inhibition of IFN-gamma activity detected after repeated cycles of IL-12. Lastly, a marked heterogeneity of cytokine induction was observed from one patient to another, which appeared to be independent of the dose of IL-12 administered. These data may lead to a better understanding of the biological activity of IL-12 and the in vivo mechanisms of its regulation.
Collapse
MESH Headings
- Antineoplastic Agents/blood
- Base Sequence
- Chemokine CXCL9
- Chemokines/blood
- Chemokines/genetics
- Chemokines, CXC/blood
- Chemokines, CXC/genetics
- Cytokines/blood
- Cytokines/genetics
- DNA Primers/genetics
- Dose-Response Relationship, Drug
- Gene Expression/drug effects
- Humans
- Intercellular Signaling Peptides and Proteins
- Interferon-gamma/blood
- Interferon-gamma/genetics
- Interleukin-10/blood
- Interleukin-10/genetics
- Interleukin-12/administration & dosage
- Interleukin-12/therapeutic use
- Interleukin-4/blood
- Interleukin-4/genetics
- Neoplasms/drug therapy
- Neoplasms/genetics
- Neoplasms/immunology
- Neovascularization, Pathologic/prevention & control
- RNA, Messenger/blood
- RNA, Messenger/genetics
- Receptors, Cytokine/blood
- Receptors, Cytokine/genetics
- Receptors, Interleukin-4/blood
- Receptors, Interleukin-4/genetics
- Recombinant Proteins/administration & dosage
- Recombinant Proteins/therapeutic use
- Solubility
- Th1 Cells/immunology
- Th2 Cells/immunology
- Tumor Necrosis Factor-alpha/genetics
- Tumor Necrosis Factor-alpha/metabolism
Collapse
Affiliation(s)
- N Haicheur
- Unité d'Immunologie Clinique, INSERM 255, Institut Curie, Paris
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Abstract
An understanding of the structure and composition of the giant planets is rapidly evolving because of (i) high-pressure experiments with the ability to study metallic hydrogen and define the properties of its equation of state and (ii) spectroscopic and in situ measurements made by telescopes and satellites that allow an accurate determination of the chemical composition of the deep atmospheres of the giant planets. However, the total amount of heavy elements that Jupiter, Saturn, Uranus, and Neptune contain remains poorly constrained. The discovery of extrasolar giant planets with masses ranging from that of Saturn to a few times the mass of Jupiter opens up new possibilities for understanding planet composition and formation. Evolutionary models predict that gaseous extrasolar giant planets should have a variety of atmospheric temperatures and chemical compositions, but the radii are estimated to be close to that of Jupiter (between 0.9 and 1.7 Jupiter radii), provided that they contain mostly hydrogen and helium.
Collapse
Affiliation(s)
- T Guillot
- Observatoire de la Côte d'Azur, Département Cassini, CNRS UMR 6529, Boîte Postale 4229, 06304 Nice Cedex 04, France.
| |
Collapse
|
13
|
Vesikari T, Joensuu J, Baer M, Käyhty H, Olander RM, Sormunen H, Miettinen A, Ward RL, Guillot T. Concurrent administration of rhesus rotavirus tetravalent (RRV-TV) vaccine with pentavalent diphtheria-pertussis-tetanus-Haemophilus influenzae beta-inactivated polio and hepatitis B vaccines. Acta Paediatr 1999; 88:513-20. [PMID: 10426173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
To investigate the incorporation of oral rhesus-human reassortant rotavirus tetravalent (RRV-TV) vaccine into a routine immunization programme, RRV-TV or oral placebo was coadministered with a pentavalent diphtheria-tetanus-whole-cell pertussis-Haemophilus influenzae b (Hib)-inactivated polio vaccine and hepatitis B vaccine following a 3-4-5-mo schedule in a double-blind trial involving 249 infants. Seroconversion rates after 3 doses of rotavirus vaccine were 80% for rotavirus immunoglobulin A (IgA) and 93% for RRV neutralizing antibodies. Rotavirus vaccine did not interfere with the immune responses to diphtheria, tetanus, pertussis, Hib, poliovirus 1, 2 and 3, or hepatitis B. Following the first, second and third doses of vaccine, fever >38 degrees C on the day of vaccination was seen in 31%, 24% and 24%, respectively, with no difference between RRV-TV- and placebo-vaccinated children. This fever was presumably due to the whole-cell pertussis vaccine. Those vaccinees who received concomitant RRV-TV vaccine had another peak of fever around d 4 after the first dose, when 25% of them had fever >38 degrees C and 3% >39 degrees C. It is concluded that RRV-TV rotavirus vaccine can be given concurrently with other childhood immunizations following a 3-4-5-mo vaccination schedule. However, febrile reactions to RRV-TV rotavirus vaccine are common when the first dose is given at the age of 3 mo.
Collapse
MESH Headings
- Antibody Formation/immunology
- Child, Preschool
- Diphtheria-Tetanus-Pertussis Vaccine/administration & dosage
- Diphtheria-Tetanus-Pertussis Vaccine/immunology
- Double-Blind Method
- Haemophilus Vaccines/administration & dosage
- Haemophilus Vaccines/immunology
- Haemophilus influenzae type b/immunology
- Hepatitis B Vaccines/administration & dosage
- Hepatitis B Vaccines/immunology
- Humans
- Immunization Schedule
- Immunoglobulin G/immunology
- Infant
- Poliovirus Vaccine, Inactivated/administration & dosage
- Poliovirus Vaccine, Inactivated/immunology
- Time Factors
- Vaccines, Attenuated/administration & dosage
- Vaccines, Attenuated/immunology
- Vaccines, Combined/administration & dosage
- Vaccines, Combined/immunology
- Vaccines, Conjugate/administration & dosage
- Vaccines, Conjugate/immunology
- Vaccines, Inactivated/administration & dosage
- Vaccines, Inactivated/immunology
- Viral Vaccines/administration & dosage
- Viral Vaccines/immunology
Collapse
Affiliation(s)
- T Vesikari
- University of Tampere Medical School, Finland.
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Chéradame S, Etienne MC, Chazal M, Guillot T, Fischel JL, Formento P, Milano G. Relevance of tumoral folylpolyglutamate synthetase and reduced folates for optimal 5-fluorouracil efficacy: experimental data. Eur J Cancer 1997; 33:950-9. [PMID: 9291820 DOI: 10.1016/s0959-8049(97)00028-2] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The purpose of this study was to investigate folate-related predictors of 5-fluorouracil (5-FU) cytotoxicity in the presence or absence of l-folinic acid (l-FA). Intracellular concentrations of the reduced folates (tetrahydrofolate + 5,10-methylenetetrahydrofolate) and folylpolyglutamate synthetase (FPGS) activity were determined in 14 human cancer cell lines expressing a spontaneous sensitivity to 5-FU. On these 14 cell lines grown without l-FA supplementation, a significant positive correlation was demonstrated between basal intracellular folate concentration and FPGS activity. 5-FU sensitivity (IC50 range 0.6-25.4 microM) was not related to the basal intracellular folate concentration, whereas, significantly, it was linked to FPGS activity (range 2.5-11.1 pmol/min/mg protein): the higher the FPGS activity, the greater the 5-FU sensitivity. Under l-FA supplementation (0.01-300 microM), intracellular reduced folates increased continuously without evidence of saturation in all cell lines; the pattern of accumulation was independent of the FPGS activity. l-FA enhanced 5-FU cytotoxicity by a factor of 1.9-6.4 in 12 of the 14 cell lines. In the 12 FA-sensitive cell lines, the l-FA concentrations allowing 90% of maximum 5-FU potentiation [l-FA]90 ranged between 0.7 and 107.9 micro M (median 1.9); in contrast, the intracellular concentrations of reduced folates allowing 90% of maximum 5-FU potentiation were much less variable (range 7.6-38.3, median 24.8 pmol/mg protein). In the presence of [l-FA]90, 5-FU sensitivity remained significantly correlated to the basal FPGS activity. In addition, reduced folates were measured in 96 tumoral samples (50 head and neck, 16 colon, 30 liver metastases from colorectal cancer) taken before treatment. Almost all investigated tumours had folate concentrations below the median concentration required for optimal 5-FU potentiation in vitro: median levels (range, pmol/mg protein) were 3.8 (0-17.7) for head and neck, 5.8 (2.3-12.0) for colon and 12.1 (1.7-118.5) for liver metastases. Above all, these data establish the relevance of FPGS activity for predicting the efficacy of 5-FU modulated by FA or not and point to the potential clinical interest of FPGS determination in human tumours.
Collapse
Affiliation(s)
- S Chéradame
- Laboratoire d'Oncopharmacologie, Centre Antoine Lacassagne, Nice, France
| | | | | | | | | | | | | |
Collapse
|
15
|
de Gramont A, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, Morvan F, Louvet C, Guillot T, François E, Bedenne L. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15:808-15. [PMID: 9053508 DOI: 10.1200/jco.1997.15.2.808] [Citation(s) in RCA: 697] [Impact Index Per Article: 25.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
PURPOSE This multicenter study compared the therapeutic ratio of a monthly schedule of low-dose leucovorin (LV) and fluorouracil (5-FU) bolus with a bimonthly schedule of high-dose LV and 5-FU bolus plus continuous infusion in patients with advanced colorectal cancer. PATIENTS AND METHODS Of the 448 patients randomly assigned to treatment, 433 were assessable. Treatment A was a monthly regimen of intravenous (IV) LV 20 mg/m2 plus bolus 5-FU 425 mg/m2 for 5 days every 4 weeks. Treatment B was a bimonthly regimen of IV LV 200 mg/m2 as a 2-hour infusion followed by bolus 5-FU 400 mg/m2 and 22-hour infusion 5-FU 600 mg/m2 for 2 consecutive days every 2 weeks. Therapy was continued until disease progression. Second-line chemotherapy, which included 5-FU continuous infusion, was allowed in both arms. RESULTS The response rates in 348 patients with measurable lesions were 14.4% (monthly regimen) and 32.6% (bimonthly regimen) (P = .0004). The median progression-free survival times were 22 weeks (monthly regimen) and 27.6 weeks (bimonthly regimen) (P = .0012). The median survival times were 56.8 weeks (monthly regimen) and 62 weeks (bimonthly regimen) (P = .067). Grade 3-4 toxicities occurred in 23.9% of patients in the monthly arm compared with 11.1% of those in the bimonthly arm (P = .0004). Patients in arm A more frequently experienced severe granulocytopenia (7.3% v 1.9%), diarrhea (7.3% v 2.9%), and mucositis (7.3% v 1.9%) than patients in arm B. CONCLUSION The bimonthly regimen was more effective and less toxic than the monthly regimen and definitely increased the therapeutic ratio. However, there was no evidence of increased survival.
Collapse
Affiliation(s)
- A de Gramont
- Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD), Hôpital Saint-Antoine, Paris, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Guillot T, Bernal ET, Janot F, Sigal R, Domenge C, Wibault P, Armand JP, Cvitkovic E. Neoadjuvant chemotherapy with cisplatin-vindesine-5-fluorouracil and folinic acid for locally advanced head and neck carcinoma. Am J Clin Oncol 1996; 19:356-62. [PMID: 8677904 DOI: 10.1097/00000421-199608000-00007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The aim of this study was to establish the feasibility, evaluate the response rate, and assess the impact on local control and survival in locally advanced (bulky nodal) squamous cell carcinoma of the head and neck (SCCHN) patients treated with neoadjuvant chemotherapy consisting of cisplatin followed by continuous infusion of vindesine and fluorouracil with intermittent i.v. folinic acid. Eligibility criteria included histologically proven SCCHN, previously untreated locally advanced stage III-IV with measurable or evaluable disease, no distant metastases, an Eastern Cooperative Oncology Group (ECOG) performance status of less than 2, patient age of at least 18 years, and adequate bone marrow, hepatic, and renal functions. The protocol consisted of three cycles (day 1, day 21, day 42) of Cisplatin (CDDP) 100 mg/m2/day i.v. on day 1 immediately followed by 4 days (96 h) of continuous infusion of vindesine 0.8 mg/m2/day and 5-fluorouracil (5-FU) 600-700 mg/m2/day with folinic acid 150 mg/m2 i.v. every 6 h x 16 doses before locoregional treatment with radiotherapy preceded by radical surgery when appropriate. Twenty-nine patients were enrolled in this study, and 28 were evaluable for activity; an objective response rate of 55% (four complete responses, 12 partial responses) was achieved. Leukopenia and mucositis were the most frequent and severe toxicities. The addition of vindesine did not improve the activity of the CDDP-FU-folinic acid combination, but this may be partly because of the particularly poor prognosis of the present patient population, with 75% of stage IV bulky nodal disease (N2c-N3).
Collapse
|
17
|
Marley MS, Saumon D, Guillot T, Freedman RS, Hubbard WB, Burrows A, Lunine JI. Atmospheric, evolutionary, and spectral models of the brown dwarf Gliese 229 B. Science 1996; 272:1919-21. [PMID: 8658164 DOI: 10.1126/science.272.5270.1919] [Citation(s) in RCA: 245] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Theoretical spectra and evolutionary models that span the giant planet-brown dwarf continuum have been computed based on the recent discovery of the brown dwarf Gliese 229 B. A flux enhancement in the 4- to 5-micrometer wavelength window is a universal feature from jovian planets to brown dwarfs. Model results confirm the existence of methane and water in the spectrum of Gliese 229 B and indicate that its mass is 30 to 55 jovian masses. Although these calculations focus on Gliese 229 B, they are also meant to guide future searches for extrasolar giant planets and brown dwarfs.
Collapse
Affiliation(s)
- M S Marley
- Department of Astronomy, New Mexico State University, Las Cruces 88003, USA.
| | | | | | | | | | | | | |
Collapse
|
18
|
Wibault P, Bensmaine MA, de Forni M, Armand JP, Tellez Bernal E, Guillot T, Recondo G, Domenge C, Janot F, Borel C, Luboinski B, Eschwege F, Cvitkovic E. Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil. J Clin Oncol 1996; 14:1192-200. [PMID: 8648374 DOI: 10.1200/jco.1996.14.4.1192] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
PURPOSE To evaluate an intensive concomitant chemoradiotherapy protocol of conventional radiotherapy with intermittent cisplatin (CDDP) and continuous-infusion fluorouracil (5-FU) in unresectable, locally advanced squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS Fifty-seven patients with unresectable stage IV MO disease (International Union Against Cancer [UICC]/American Joint Committee on Cancer [AJCC], 1987) received radiotherapy 70 Gy followed by CDDP 80 mg/m2 and 5-FU 300 mg/m2/d. Response was assessed 2 months after treatment completion. RESULTS Thirty patients (52%) received the full treatment schedule; 53 (93%) received full-dose radiotherapy, while 48 (84%) were given at least 75% of the planned chemotherapy doses. Severe mucositis (World Health Organization [WHO]) grade 3 to 4 was the limiting toxicity and was seen in 79% of patients. The median time for mucositis resolution was 8 weeks. Other toxicities were generally manageable, but there were four treatment related deaths (7%). Fifty patients were assessable for activity, with an overall response rate of 70% (95% confidence interval [CI], 58% to 82%). Complete response (CR) and partial response (PR) rates were 42% and 28%, respectively. CONCLUSION This simultaneous combined-modality regimen was feasible at the cost of severe mucosal toxicity, which required hospitalization with nutritional, parenteral, and hydroelectrolytic support. The high response rate achieved (70%) did not translate into improved survival, probably due to patient eligibility. The likelihood of cure of this high-tumoral-volume patient population remains low (approximately 10%), despite the association of two therapeutic modalities at full standard therapeutic intensity.
Collapse
Affiliation(s)
- P Wibault
- Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Abstract
BACKGROUND The 5-fluorouracil (FU)-folinic acid (FA) association has demonstrated clinical efficacy in colorectal cancer, both in adjuvant and metastatic situations. However, there is no clear consensus about the optimal FU-FA schedule and dose. In addition, it would be of interest to identify FU-FA-responsive tumors. DESIGN Our purpose was to review preclinical and clinical data dealing with prediction of FU-FA sensitivity and optimization of FU-FA schedules. RESULTS Preclinical studies have highlighted the importance of thymidylate synthase (TS), the cellular target of the FU-FA mechanism of action, for predicting FU sensitivity. It appears that the more sensitive cell lines express the lowest TS activity. Interestingly, the cell lines sensitive to FA supplementation are those more sensitive to FU. The role of TS in FU-FA responsiveness has been clearly demonstrated in patients with colorectal and gastric cancers. Preliminary in vitro and clinical data have shown that the folylpolyglutamate synthetase (FPGS), the enzyme responsible for folate polyglutamylation, is another promising tool for identifying FU-FA-responsive tumors. So far, results of clinical trials do not form a clear consensus regarding the need to administer high FA doses for improving FU-FA treatment. Experimental studies on human cancer cell lines have demonstrated the wide variability among cell lines, ranging from 0.05 to 200 microns, of 1 FA concentrations required for maximal FU potentiation. In addition, pharmacokinetic studies have reported a significant variability of active folates in plasma after administration of standard-dose FA. Altogether, these observations favour high-dose FA administration to achieve high folate concentrations in plasma and thus to counteract the variability of the 1 FA concentrations required. With respect to the choice of FU-FA schedule, it appears from experimental data that increasing the duration of exposure to FA enhances FU-FA cytotoxicity, probably through an increased formation of reduced folate polyglutamate forms. Considering the S-phase specificity of FU cytotoxicity as well as its rapid elimination from plasma, a schedule of prolonged exposure to both FU and FA should be considered preferable. CONCLUSIONS Results of the new FU-FA administration schedules such as the one consisting of a 2-hour FA administration followed by a combination of FU bolus and FU infusion, or the chronomodulated FU-FA infusion, open up promising approaches for improving the therapeutic index of FU-FA chemotherapy. Finally, future clinical studies should investigate tumoral parameters pharmacologically linked to FU-FA sensitivity such as pre-treatment TS and FPGS activities. Such tumoral investigations along with FU and FA pharmacokinetic investigations should provide a better understanding of inter-patient variability in response to FU-FA therapy and an optimal management of this chemotherapy regimen.
Collapse
|
20
|
Basset J, De Grammont A, Milan C, Rougier P, Bouche O, Etienne P, Morvan F, Louvet C, Guillot T, Bedenne L. 702 Randomized phase III trial comparing 5FU bolus and low dose leucovorin versus 5FU bolus plus continuous 5FU infusion and high dose LV in metastatic colorectal cancer. Eur J Cancer 1995. [DOI: 10.1016/0959-8049(95)95952-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
21
|
Abstract
The condensation of chemical species of high molecular mass such as methane, ammonia, and water can inhibit convection in the hydrogen-helium atmospheres of the giant planets. Convection is inhibited in Uranus and Neptune when methane reaches an abundance of about 15 times the solar value and in Jupiter and Saturn if the abundance of water is more than about five times the solar value. The temperature gradient consequently becomes superadiabatic, which is observed in temperature profiles inferred from radio-occultation measurements. The planetary heat flux is then likely to be transported by another mechanism, possibly radiation in Uranus, or diffusive convection.
Collapse
Affiliation(s)
- T Guillot
- Lunar and Planetary Laboratory, University of Arizona, Tucson 85721, USA
| |
Collapse
|
22
|
Schneider M, Etienne MC, Milano G, Thyss A, Otto J, Dassonville O, Mobayen H, Saudes L, Guillot T, Demard F. Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. J Clin Oncol 1995; 13:1656-62. [PMID: 7602355 DOI: 10.1200/jco.1995.13.7.1656] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
PURPOSE To analyze clinical and pharmacokinetic data of cisplatin (CP)/fluorouracil (FU)/l folinic acid (l FA) chemotherapy administered as first-line treatment to locally advanced head and neck cancer patients. PATIENTS AND METHODS Thirty-nine patients (35 men and four women; median age, 60 years; six stage III and 33 stage IV) received CP on day 1 (100 mg/m2) followed by l FA (200 mg/m2/d x 5) plus FU (500 mg/m2/d x 5) administered by continuous venous infusion (three cycles planned). Mean plasma concentrations of FU, l FA, and 5-methyltetrahydrofolate (5MTHF) over the cycle were computed. RESULTS Clinical response was assessable for 33 patients. Response rates on the primary tumor site (n = 33) were 63.7% complete responses (CRs), 24.2% partial responses (PRs), and 12.1% treatment failures. Response rates on lymph nodes (n = 27) were 40.7% CRs, 37.1% PRs, and 22.2% treatment failures. The most frequent toxicity was mucositis (36.2% of cycles grade 3 to 4). Grade 3 to 4 nausea-vomiting, diarrhea, neutropenia, and thrombocytopenia occurred in 6.7%, 1.9%, 13.3%, and 1% of cycles, respectively. Pharmacokinetic analysis showed a wide interpatient variability for both FU (mean, 1.01 mumol/L; range, 0.16 to 2.09), l FA (mean, 1.89, mumol/L; range, 0.52 to 7.88) and 5MTHF plasma concentrations (mean, 3.85 mumol/L; range, 1.30 to 8.11). A significant correlation was demonstrated between FU concentration and hematologic toxicity grade, mucositis grade, and nausea-vomiting/diarrhea grade. Regarding tumor response, patients who failed to respond significantly exhibited lower FU and total folate concentrations than patients with a CR or PR. CONCLUSION This study highlights the efficacy of CP/FU/l FA in head and neck carcinoma and establishes the clinical importance of coupled FU/FA pharmacokinetics to predict pharmacodynamic variability.
Collapse
|
23
|
Burrows A, Saumon D, Guillot T, Hubbard WB, Lunine JI. Prospects for detection of extra-solar giant planets by next-generation telescopes. Nature 1995. [DOI: 10.1038/375299a0] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
24
|
Beck A, Etienne MC, Chéradame S, Fischel JL, Formento P, Guillot T, Milano G. Wide range for optimal concentration of folinic acid in fluorouracil modulation--experimental data on human tumour cell lines. Eur J Cancer 1994; 30A:1522-6. [PMID: 7833112 DOI: 10.1016/0959-8049(94)e0063-a] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The clinical use of the fluorouracil (FU)-folinic acid (FA) combination is hampered by the still open choice of the optimal schedule, with marked controversy as concerns the optimal FA dose. This in vitro study on FU-FA combinations in 17 human cancer cell lines, representative of tumour types responding to FU-FA treatment, reassesses the notion of the optimal FA concentration. Cells were exposed for 5 days to various FU-FA concentrations (0.07-77 microM, 14 concentrations, for FU; and 0.0025-100 microM for FA). The growth inhibition was assessed by the MTT test. The investigated cell lines exhibited FU IC50 ranging from 0.4 to 38.9 microM (median 3.7 microM). In six out of 17 cell lines investigated, the addition of FA did not result in a substantial enhancement of FU cytotoxicity (group 1). For the remaining 11 cell lines responding to FA supplementation (group 2), the maximal enhancement factor ranged from 3 to 8, meaning that in the presence of optimal FA concentration, the efficient FU concentration (IC50) was reduced by between 3 and 8 as compared to the efficient FU concentration without FA supplementation. For cell lines responding to FA supplementation, the optimal FA concentrations ranged from 10(-7) to 4 x 10(-4) M (4000-fold range) with a median value at 9.6 x 10(-7) M. Distribution of cell doubling time was not significantly different between group 1 and group 2. In contrast, the FU IC50 were significantly different (P = 0.02) between group 1 (median 7.4 microM) and group 2 (median 2.2 microM), thus indicating that cell lines with the greatest FU cytotoxicity enhancement by FA were those intrinsically sensitive to FU and vice versa.
Collapse
Affiliation(s)
- A Beck
- Centre Antoine Lacassagne, Nice, France
| | | | | | | | | | | | | |
Collapse
|
25
|
Leblanc T, Deméocq F, Leverger G, Baruchel A, Lemerle S, Vannier JP, Nelken B, Guillot T, Schaison G. Treatment of relapsed or refractory acute leukemia in childhood with bisantrene combined with high dose aracytine. Med Pediatr Oncol 1994; 22:119-24. [PMID: 8259097 DOI: 10.1002/mpo.2950220211] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Bisantrene is an anthracene derivative which has demonstrated activity in acute myeloblastic leukemia (AML) and in lymphoma. The present study was designed to assess the reinduction rate and toxicity of bisantrene (250 mg/m2/d x 5) associated with aracytine (100 mg/m2 twice a day x 5) in refractory and relapsed acute childhood leukemia. Patients who relapsed after bone marrow transplantation were eligible. Twenty-six children were included. Diagnoses were as follows: 13 AML, 9 acute lymphoblastic leukemia (ALL), and 4 undifferentiated leukemia (AUL). All patients had been very highly pretreated, especially with anthracyclines, and most of them were of poor prognosis. The overall response rate was 46% with a 95% confidence interval ranging from 27-65%. According to diagnosis, complete remission (CR) rates are: AML: 5/13, ALL: 5/9, and AUL: 2/4. Four children died, three from infection and one from acute lysis syndrome. The major toxicity was infection with grade 3 and 4 episodes occurring in 42% of patients. No significant cardiac toxicity was noted. Hepatic and renal toxicity was noted. Hepatic and renal toxicity were limited and transient. Bisantrene in association with aracytine is effective in both AML and ALL of childhood. Bisantrene should be evaluated with a five-day schedule in other pediatric malignancies. In children with acute leukemia previously treated with high dose aracytine, new combination regimen is warranted.
Collapse
Affiliation(s)
- T Leblanc
- Hôpital Saint-Louis, Paris, Hôtel-Dieu, France
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Spielmann M, Gandia D, Fizazi K, Guillot T, Cvitkovic E, Kayitalire L, Girinsky T, Elias D, Rougier P, Kac J. Phase II study of 4'epirubicin in advanced squamous cell oesophageal cancer. Eur J Cancer 1994; 30A:1908-9. [PMID: 7880628 DOI: 10.1016/0959-8049(94)00254-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
27
|
Etienne MC, Fischel JL, Formento P, Schneider M, Guillot T, Bardon M, Milano G. Combination of reduced folates with methotrexate or 5-fluorouracil. Comparison between 5-formyltetrahydrofolate (folinic acid) and 5-methyltetrahydrofolate in vitro activities. Biochem Pharmacol 1993; 46:1767-74. [PMID: 8250962 DOI: 10.1016/0006-2952(93)90581-g] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Folinic acid (dlFA) is increasingly used in clinical oncology. The active isomer lFA is intensively metabolized into l5-methyltetrahydrofolate (l5MTHF), the relative proportions of lFA, dFA and l5MTHF in blood varying considerably between oral and i.v. FA administration. The purpose of the study was to compare the in vitro activities of pure lFA and pure l5MTHF at equivalent drug exposure [area under curve (AUC)], taking into account their respective chemical stability in the culture medium. The in vitro growth inhibition [3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) test] was evaluated on five human tumor cell lines after methotrexate (MTX)-folate or 5-fluorouracil (5FU)-folate exposures. Not only were the activities of lFA and l5MTHF compared, but also clinically relevant mixtures of lFA + dFA + l5MTHF corresponding to the proportions found at steady state during oral (PO mixture, 4, 39 and 57%, respectively) and i.v. administrations (i.v. mixture, 7, 81 and 12%, respectively). Measurement of folates demonstrated the marked lability of l5MTHF (65.8% loss over 5 days in the culture medium) as compared to lFA (2.6% loss). Whatever the pharmacological model tested (MTX-folate or 5FU-folate), comparison of the folate effects at equivalent drug exposure taking into account their relative stability showed that l5MTHF was never more potent than lFA. Moreover, a higher efficiency of lFA was demonstrated for the cell line most sensitive to 5FU; in this case, as expected, the i.v. mixture was more potent than the PO mixture. This study shows that depending on the tumor, lFA can be more potent than its main circulating metabolite l5MTHF. Along with the limited capacity of oral absorption, the choice between oral and i.v. route for FA administration in patients should take into consideration the different pharmacological activities between lFA and l5MTHF which suggest that the oral route is potentially detrimental to the optimal activity of the 5FU-FA combination as compared to i.v. administration.
Collapse
|
28
|
Louvet C, de Gramont A, Demuynck B, Beerblock K, Varette C, Soubrane D, Marpeau L, Pigné A, Guillot T, Krulik M. Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer. Eur J Cancer 1993; 29A:1835-8. [PMID: 8260236 DOI: 10.1016/0959-8049(93)90532-k] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
60 patients with metastatic breast cancer were entered in a phase II study using folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide. 47 had measurable visceral metastases and 13 had exclusively bone metastases. 36 had received previous adjuvant or metastatic treatment (33/36 with anthracycline-based regimens). Overall response rate in visceral metastatic patients was 57.1% [95% confidence interval (CI) 35.4-78.8%]; 45.5% and 70% in previously and non-previously treated patients, respectively; duration of response was 9 and 13 months, respectively. 10 out 13 patients with exclusive bone metastases improved for a median time of 18 months. Median survival was 22 months for the 60 patients; 18 and 31 months for previously and non-previously treated patients, respectively. Cyclophosphamide was scheduled only in the absence of nadir grade 4 neutropenia. However, this toxicity occurred in the first 7 patients. For this reason, we chose to avoid cyclophosphamide in patients over 60 years, or with a performance status of 1-2, or who had received previous chemotherapy. Overall, cyclophosphamide was stopped due to nadir grade 4 neutropenia in 17/24 patients for whom this drug was planned. When mitoxantrone, 5-fluorouracil and folinic acid were used at the doses scheduled, the addition of cyclophosphamide appeared feasible in only about 25% of the patients. Furthermore, survival was identical for patients receiving or not receiving cyclophosphamide. Therefore, cyclophosphamide does not contribute substantially to this regimen. This study confirms the value of folinic acid, 5-fluorouracil and mitoxantrone in metastatic breast cancer.
Collapse
Affiliation(s)
- C Louvet
- GERCOD, Hôpital Saint-Antoine, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Gandia D, Wibault P, Guillot T, Bensmaine A, Armand JP, Marandas P, Luboinski B, Cvitkovic E. Simultaneous chemoradiotherapy as salvage treatment in locoregional recurrences of squamous head and neck cancer. Head Neck 1993; 15:8-15. [PMID: 7677989 DOI: 10.1002/hed.2880150103] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
This study was designed to determine if long-term palliation could be obtained in pre-irradiated locoregional recurrent squamous head and neck cancer patients, with the administration of simultaneous chemoradiotherapy. Mandatory eligibility criteria were histologically documented squamous head and neck cancer in previously irradiated territory, surgical or brachytherapy salvage unfeasibility, or patient refusal. The protocol consisted of radiotherapy, at a rate of 5 daily fractions of 2 Gy on alternate weeks, with simultaneous continuous intravenous infusion of 5-fluorouracil (5FU) at 800 mg/m2 and oral hydroxyurea (HU) at 1,000-1,500 mg/day for 5 days. Tolerance was good. Acute toxicity was low with no grade > or = III WHO hematologic toxicity observed. Nine patients had grade III mucositis, one had grade IV, three had grade III skin toxicity, and only four patients required a 20% to 30% 5FU dose reduction because of it. Two patients had hand and foot syndrome, and two had asymptomatic 5FU-related cardiac signs (1 ECG, 1 echographic+ECG). Chronic radiotherapy-related effects consisted of Hermitte's sign observed in two patients. Of 34 registered patients, 33 were evaluable for response. An overall rate of 55% (18 patients) of objective responses [complete response (CR) + partial response (PR)] was obtained, with 12 patients (36%) achieving local control of disease. The median survival was 11 months. These data show that palliation could be obtained for the majority of responding patients, and also suggest an improvement in the immediate prognosis with this type of salvage procedure for a selected group of recurrent squamous head and neck cancer patients.
Collapse
Affiliation(s)
- D Gandia
- Department of Head and Neck Surgery, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Bensmaine A, Borel C, Wibault P, Cvitkovic E, Schwaab G, Recondo G, Domenge C, de Forni M, Guillot T, Luboinski B, Eschwege F, Armand J. Intensive simultaneous chemoradiotherapy (CT-RT) in locally advanced head and neck squamous cell carcinoma (HNSCC). Eur J Cancer 1993. [DOI: 10.1016/0959-8049(93)91378-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
31
|
Machover D, Grison X, Goldschmidt E, Zittoun J, Lotz JP, Metzger G, Richaud J, Hannoun L, Marquet J, Guillot T. 5-Fluorouracil combined with the pure [6S]-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study of two consecutive regimens. Adv Exp Med Biol 1993; 339:81-95; discussion 97-8. [PMID: 8178732 DOI: 10.1007/978-1-4615-2488-5_10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Affiliation(s)
- D Machover
- Department of Oncology, Hospital Tenon, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Lagrange JL, Fischel JL, Galliani S, Formento P, Guillot T, Bardon M, Milano G. Importance of the irradiation timing within a chemoradiotherapy sequence including cisplatin and 5-FU-folinic acid. Experimental results. Eur J Cancer 1993; 29A:1531-5. [PMID: 8217357 DOI: 10.1016/0959-8049(93)90289-r] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The objective of the present in vitro study was to determine an optimal timing of the irradiation in the combination cisplatin (CDDP) and 5-fluorouracil-folinic-acid (5-FU-FA) allowing a maximal cytotoxic effect on a human cell line derived from a head and neck carcinoma (CAL 27 cells). The various tested chemoradiotherapy sequences were applied in parallel to human keratinocytes in culture (SVK 14 cells). This was done in order to define the best sequence allowing the achievement of an optimal selectivity of the cytotoxic effects. The drug sequence was: CDDP over 2 h then fresh medium was added including the tandem 5-FU-d,I FA applied 6 h after CDDP, for 5 days. Irradiation was applied only once and at various times within the drug sequence. The cytotoxicity effects of the different chemoradiotherapy combinations were assessed by the MTT semi-automated test. The part taken by the 5-FU-FA combinations in the overall cytotoxicity was examined; an effect was apparent on CAL 27 cells only. The evolution of the radiation effect (RE = cell survival after drugs/cell survival after drugs plus irradiation) was analysed as a function of the different times of irradiation within the given drug sequence. Clearly, the RE values were dependent upon time at which the radiation dose in the chemoradiotherapy regimen was administered. For CAL 27 cells, irradiation effects were maximal at the first irradiation time tested after the end of the CDDP exposure (i.e. t = 3.5 h). In contrast, this optimal chemoradiotherapy timing for better cytotoxicity on CAL 27 cells did not correspond to that of SVK 14 cells. Consequently, it was possible to establish that the best time for the selectivity index was located shortly after the CDDP exposure.
Collapse
Affiliation(s)
- J L Lagrange
- Centre Antoine-Lacassagne, Radiotherapy Unit, Nice, France
| | | | | | | | | | | | | |
Collapse
|
33
|
Milano G, Etienne MC, Cassuto-Viguier E, Renée N, Bousselet M, Guillot T, Lecompte D. Long-term stability of 5-fluorouracil and folinic acid admixtures. Eur J Cancer 1993; 29A:129-32. [PMID: 1445730 DOI: 10.1016/0959-8049(93)90590-c] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
5-Fluorouracil (5-FU) and d,1-folinic acid (FA) are used in association to treat a wide variety of malignancies. The stability and the compatibility of 5-FU and FA in combination in intravenous admixtures were studied under various storage conditions and with drug concentrations matching their clinical use (0.9% sodium chloride, 5% dextrose, protected from light or not). 5-FU and FA concentrations (mg/ml) were 6.5 or 50 and 4.0 or 30.8, respectively. Successive aliquots of the drugs mixtures were withdrawn during 60 h from 500 ml glass bottles and 500 ml polyvinyl chloride (PVC) bags (at room temperature) and during 120 h from cassettes (at 32 degrees C). Drug concentrations were measured by high performance liquid chromatography. For all conditions tested, the changes in 5-FU and FA relative to the initial concentrations remained within the assay reproducibility (10%). In complement, infrared Fourier transformation spectrophotometry has not shown a significant fixation of FA or 5-FU on the PVC bags, in all tested conditions. Under the conditions examined above 5-FU and FA can be mixed in the same container for their use in cancer chemotherapy. This can have practical consequences by simplifying the widely used treatment protocols associating 5-FU and FA.
Collapse
Affiliation(s)
- G Milano
- Centre Antoine-Lacassagne, Laboratoire d'Oncopharmacologie, Nice, France
| | | | | | | | | | | | | |
Collapse
|
34
|
Machover D, Grison X, Goldschmidt E, Zittoun J, Lotz JP, Metzger G, Richaud J, Hannoun L, Marquet J, Guillot T. Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study. J Natl Cancer Inst 1992; 84:321-7. [PMID: 1738182 DOI: 10.1093/jnci/84.5.321] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
BACKGROUND Potentiation of the antitumor activity of fluorouracil (5-FU) by folinic acid has been demonstrated in patients with colorectal adenocarcinoma. Modulation is due to the interaction of thymidylate synthase, fluorodeoxyuridine monophosphate, and methylene tetrahydrofolate, which leads to the formation of a stable ternary complex with concomitant enzyme inactivation. Folinic acid consists of a mixture of equal parts of two stereoisomers differing in chirality at the C-6 carbon of the pteridine ring. Only the levorotatory (6S)-stereoisomer of folinic acid is transformed into active folate cofactors. However, the (6R)-stereoisomer of folinic acid is not inert; it was shown to interfere with the (6S) form at the cellular level. PURPOSE The possibility of a deleterious effect of the unnatural stereoisomer on the modulation of 5-FU led us to carry out a phase I-II study of 5-FU combined with the (6S)-stereoisomer of folinic acid given in high doses for treatment of patients with advanced colorectal carcinoma. We also determined the plasma pharmacokinetics of folates after intravenous (IV) injection of (6S)-folinic acid at the dose used in this study. METHODS Treatment consisted of 5-FU (350-550 mg/m2 per day by IV infusion for 2 hours) and (6S)-folinic acid (100 mg/m2 per day by IV bolus injection) given for 5 consecutive days; the treatment was repeated every 21 days. Twenty-five patients with advanced colorectal carcinoma, who had had no prior chemotherapy, were evaluated for antitumor activity. The quantity of folates in plasma was measured using a microbiological assay. RESULTS The median follow-up time was 9 months (range, 3.5-15.2 months). The response rate was 52% (complete response, 12%; partial response, 40%). The median time to disease progression for responding patients was 9.2 months (range, 5.9-15+ months). The estimated probability of survival at 12 months was 73%. Palliative improvement in quality of life was achieved in most patients who had symptoms due to the tumor before the start of treatment. The dose-limiting toxic effects were grade 3 diarrhea, dermatitis, and oral mucositis. Grade 4 toxicity did not occur. Myeloid toxicity was minor. After IV injection, (6S)-folinic acid was rapidly cleared from plasma (mean half-lives: alpha = 7.2 minutes and beta = 126 minutes). The mean concentration of the unchanged compound 2 hours after injection was 5.8 mumol/L. CONCLUSION The (6S)-form of folinic acid potentiates the antitumor effect of 5-FU given concomitantly. IMPLICATION Our results justify a more complete exploration of the pure active stereoisomer as a modulator of the fluoropyrimidines.
Collapse
|
35
|
Guillot T, Spielmann M, Kac J, Luboinski B, Tellez-Bernal E, Munck JN, Bachouchi M, Armand JP, Cvitkovic E. Neoadjuvant Chemotherapy in Multiple Synchronous Head and Neck and Esophagus Squamous Cell Carcinomas. Laryngoscope 1992; 102:311-9. [PMID: 1372059 DOI: 10.1288/00005537-199203000-00013] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
A consecutive series of 22 patients with multiple synchronous squamous cell carcinomas of the upper aerodigestive tract was retrospectively reviewed. These patients were treated initially with cis-platinum combination chemotherapy before definitive locoregional therapy (surgery and/or radiation therapy). Sixteen of 21 patients had simultaneous head and neck and esophageal primaries, 3 patients had multiple synchronous head and neck primaries, 2 patients had head and neck (HN) and a bronchial epidermoid cancer, and 1 patient had simultaneous esophageal and bronchial carcinomas of epidermoid lineage. Sixteen (77%) of the 21 patients responded to chemotherapy in all the tumor sites evaluated, and a clinically complete response was obtained in 6 (29%). After definitive locoregional treatment, the complete local control rate was 68%, with 34 complete responses for 50 primary tumor sites in 21 patients. Twelve patients were free of disease after locoregional treatment. Six patients are still alive 27 to 57 months after complementary definitive locoregional treatment and a minimum follow-up of 27 months. Median survival for the overall group is 17 months. The response to chemotherapy is remarkable, which may be due to the small tumoral volume present in many of the cases (T1 to T2). Nevertheless, the present report stresses the importance of an aggressive combined therapeutic approach in this difficult clinical situation.
Collapse
Affiliation(s)
- T Guillot
- Institut Gustave-Roussy, Savigny-le-Temple, France
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Gandia D, Spielmann M, Kac J, Elias D, Girinsky T, Guillot T, Rougier P. Cerebrovascular accident associated with chemotherapy for oesophageal carcinoma. Eur J Cancer 1992; 28:245. [PMID: 1567673 DOI: 10.1016/0959-8049(92)90421-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
37
|
Tellez-Bernal E, Recondo G, Guillot T, Benhamed M, Domenge C, Izzo J, Cvitkovic E, Armand JP. A phase II study of cisplatin and continuous infusion of vindesine in metastatic head and neck squamous cell cancer. Cancer 1990; 66:640-4. [PMID: 2386892 DOI: 10.1002/1097-0142(19900815)66:4<640::aid-cncr2820660406>3.0.co;2-d] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The chemotherapeutic treatment of recurrent and/or metastatic squamous cell carcinoma (SCC) of the head and neck (H & N) has a very dismal prognosis, with survival usually not exceeding 1 year. Reported objective response rates vary between 3% and 70%. This difference appears largely attributable to the heterogeneity of the patient populations included in most published Phase II studies in H & N cancer. They usually include together initially metastatic, recurrent, and post primary treatment metastatic disease patients. These patients respond differently to chemotherapy. Because of this situation, we decided to study a more homogeneous patient population consisting of metastatic patients only. Cisplatin (CDDP) and vindesine (VDS) are active agents in H & N SCC. As VDS has a cycle-specific activity, the therapeutic index may be increased if it is administered in a continuous infusion (CI) schedule. Thirty-three patients with metastatic H & N (69% biopsy proven) were treated with a combination regimen including CDDP (100 mg/m2) day 1 and VDS 0.6 to 1 mg/m2 for 96 hours of CI. Thirty-one patients were evaluable for response: five had a complete response (CR; 16%) and 11 had a partial response (PR; 36%) with an overall rate response of 52% (95% confidence limit: 33% to 70%). Median duration of CR was 6.4 months (3 to 19 months) and 4.4 months for PR (3 to 6 months). A decrease in the leukocytes was the main toxicity encountered with this regimen. This combination regimen containing CDDP and CI VDS was well tolerated and active in H & N SCC. The incorporation of an active vinca-alkaloid in neoadjuvant regimens should be considered.
Collapse
Affiliation(s)
- E Tellez-Bernal
- Department of Medicine, Institut Gustave-Roussy-Villejuif, France
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Fermé C, Guillot T, Frija J, Miot C, Gisselbrecht C, Fermand JP, Baud L. [Early post-radiation pericardial changes in Hodgkin's disease. Value of x-ray computed tomography]. Presse Med 1986; 15:1360-3. [PMID: 2950410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Eighteen patients with mediastinal Hodgkin's disease treated with chemotherapy first, then irradiation were investigated during 1 year by means of 5 CT and radiological examinations of the chest. Four months after irradiation pericardial thickening was detected in 60 p. cent of the patients. The authors underline the high frequency, early occurrence and usually spontaneous resolution of radiation-related pericarditis without clinical or radiological signs.
Collapse
|